Bristol-Myers Squibb Enters into Exclusive Worldwide License and Collaboration Agreement with Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody Program
Go back to Bristol-Myers Squibb Enters into Exclusive Worldwide License and Collaboration Agreement with Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody Program| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 63.06 +0.22 (0.35%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $62.84 | 52 Week High | $77.12 | |||
| Open | $62.71 | 52 Week Low | $49.03 | |||
| Day High | $63.07 | P/E | 40.95 | |||
| Day Low | $62.19 | EPS | $1.54 | |||
| Volume | 36,848,550 | |||||
| FIVE PRIME THER (NASDAQ: FPRX) | Delayed: 38.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $38.00 | 52 Week High | $57.79 | |||
| Open | $43.46 | 52 Week Low | $28.01 | |||
| Day High | $38.00 | P/E | N/A | |||
| Day Low | $38.00 | EPS | $-2.50 | |||
| Volume | 329,789 | |||||
